(NASDAQ: RXRX) Recursion Pharmaceuticals's forecast annual revenue growth rate of 41.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.27%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Recursion Pharmaceuticals's revenue in 2025 is $59,790,000.On average, 4 Wall Street analysts forecast RXRX's revenue for 2025 to be $29,831,459,426, with the lowest RXRX revenue forecast at $18,231,713,883, and the highest RXRX revenue forecast at $46,950,189,594. On average, 4 Wall Street analysts forecast RXRX's revenue for 2026 to be $38,030,060,066, with the lowest RXRX revenue forecast at $18,292,281,660, and the highest RXRX revenue forecast at $71,339,898,474.
In 2027, RXRX is forecast to generate $83,989,620,985 in revenue, with the lowest revenue forecast at $29,567,644,075 and the highest revenue forecast at $138,411,597,894.